Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
|
|
Sexually Transmitted Infections Vol. 83; No. 6: P. 441-446 (10.01.07) - Thursday, December 27, 2007
L. Barham; D. Lewis; N. Latimer
Four electronic bibliographic databases from 1990 to January 2006 were searched using keywords including: teenage, pregnancy, adolescent, unplanned, unwanted, cost benefit, cost utility, economic evaluation, cost effectiveness and all terms for STDs, including specific disease names. Studies were included that assessed a wide range of one-to-one interventions aimed at reducing STDs. Outcomes included major outcomes averted, life years and quality-adjusted life years (QALY). All studies were assessed against quality criteria.
The researchers identified 3,190 papers, of which 55 were included. Most studies found one-to-one interventions were either cost-saving or cost-effective. One, however, highlighted the need to target the population to receive post- exposure prophylaxis to reduce HIV transmission. Most of the studies employed a static approach that does not consider the potential re-infection of treated patients.
"One-to-one interventions have been shown to be cost-saving or cost-effective, but there are some limitations in applying this evidence to the UK policy context," the authors concluded. "More UK research using dynamic modeling approaches and QALY would provide improved evidence, enabling more robust policy recommendations to be made about which one-to-one interventions are cost-effective in reducing [STDs] in the UK setting. The results of this review can be used by policy makers, health economists, and researchers considering further research in this area."
071227
AD072687
Copyright © 2007 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.